The Food and Drug Administration (FDA) has granted Priority Review for for elranatamab, an investigational B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody (BsAb), for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). The FDA’s decision on the application is expected in 2023. Additionally, the European Medicines Agency (EMA) has also accepted elranatamab’s marketing authorization application (MAA).

Read the full press release for details.